Discover how rheumatoid arthritis advances through distinct stages, the symptoms at each phase, and treatment approaches that ...

CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing -HAMPTON, N.J., ...

The relationship between food allergies and chronic illness represents one of the most significant yet underappreciated ...

This oversubscribed Series A funding round was led by General Catalyst with additional investment from new investors, British ...

CDX-622 is a bispecific antibody that targets two complementary, clinically validated pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP ...

The interplay between cortisol, inflammation, and disease underscores the need for effective stress management to enhance ...

US-based startup Bambusa Therapeutics has secured $90m in Series A financing to advance its pipeline of bispecific antibodies for immunological and inflammatory disorders into the clinic.

Mestag Therapeutics, a leading biotech company specialising in fibroblast immunology for inflammatory disease and cancer, has ...

Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with a weakened ...

In a new study on mice, an experimental antibody treatment reduced the lingering after-effects of head injuries.